FDA Sends Byondis Complete Response Letter Delaying Decision on HER2-Positive Breast Cancer Drug
Byondis submitted data on SYD985's activity from the Phase III TULIP trial, but the agency has requested additional information.
In Brief This Week: Kinnate Biopharma, HuidaGene Therapeutics, Epic Bio, Dante Genomics
News items for the week of April 17, 2023.
In Brief This Week: Centogene, DermTech, Nicklaus Children's Hospital, Daiichi Sankyo, AstraZeneca
News items for the week of April 10, 2023.
In Brief This Week: Ellipses Pharma, Perspective Therapeutics, Exscientia, Deciphera Pharmaceuticals
News items for the week of March 13, 2023.
ALX Oncology's Evorpacept Enters I-SPY-P1 Breast Cancer Trial in Combination With Enhertu
Trial sponsor Quantum Leap Healthcare Collaborative will test the combination in patients with HER2-positive and HER2-low unresectable or metastatic breast cancer.
Jan 4, 2023
Aug 11, 2022